Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9104686 | 0.90 | PTPN1 (0.46) | PTPN1HDAC1HDAC6HDAC5HDAC8 | |
| SCHEMBL9104995 | 0.86 | PTPN1 (0.46) | PTPN1HDAC1HDAC6HDAC5HDAC8 | |
| SCHEMBL27920264 | 0.82 | PTPN1 (0.46) | PTPN1HDAC1HDAC6HDAC5HDAC8 | |
| SCHEMBL9912337 | 0.80 | PTPN1 (0.44) | PTPN1HDAC1HDAC6HDAC8 | |
| SCHEMBL9280647 | 0.79 | PTPN1 (0.44) | PTPN1 | |
| SCHEMBL9100890 | 0.79 | PTPN1 (0.48) | PTPN1 | |
| SCHEMBL9104545 | 0.79 | S1PR5 (0.53) | — | |
| SCHEMBL9913930 | 0.78 | PTPN1 (0.44) | PTPN1 | |
| SCHEMBL10032054 | 0.78 | MDM2 (0.35) | HDAC1HDAC6HDAC5HDAC8 | |
| SCHEMBL9103709 | 0.77 | S1PR1 (0.55) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142639-A1 | OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142639-A1 | OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR3, S1PR1, S1PR2 | PTPN1 1043/4885HDAC1 1239/4885HDAC6 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.